"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
| Descriptor ID |
D020533
|
| MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
| Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 2 | 4 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 3 | 5 |
| 2012 | 3 | 3 | 6 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 3 | 7 |
| 2015 | 7 | 1 | 8 |
| 2016 | 5 | 1 | 6 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 3 | 5 |
| 2022 | 2 | 1 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 3 | 6 |
| 2025 | 2 | 1 | 3 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs. 2016 12; 34(6):685-692.
-
Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. Br J Cancer. 2015 Nov 03; 113(9):1282-8.
-
Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. Oncologist. 2015 Oct; 20(10):1140-8.
-
Wound healing complications in brain tumor patients on Bevacizumab. J Neurooncol. 2015 Sep; 124(3):501-6.
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
-
New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):58-65.
-
Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol. 2014 Aug; 119(1):135-40.
-
Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014 May; 14(5):443.
-
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014 Apr 30; 5(8):2208-20.
-
Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014 May; 24(5):918-22.